Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia
In the register
The register attaches this trial to VDPHL-01 (oral minoxidil) (Veradermics), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Active, not recruiting
- Declared phase
- Phase 3
- Sponsor
- Veradermics, Inc.
- Participants (registry)
- 552
- Start
- July 2025
- Primary completion
- June 2027 (planned)
- Study completion
- January 2028 (planned)
- Last registry update
- August 2026
- Countries
- United States
Conditions studied: Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Interventions: VDPHL01 QD, Placebo, VDPHL01 BID, Placebo
Other trials of VDPHL-01 (oral minoxidil)
Safety and Efficacy of VDPHL01 in Males With AGA
Efficacy and Safety of VDPHL01 in Males With AGA
Safety and Efficacy of VDPHL01 in Males and Females With AGA
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.